Sosei Group (JP:4565) has released an update.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Nxera Pharma reports positive Phase 2 results for NBI-1117568, a potential new once-daily oral treatment for schizophrenia showing significant symptom improvement. Developed in partnership with Neurocrine Biosciences, the drug met primary and secondary endpoints with good safety and tolerability. This success paves the way for Phase 3 trials and highlights the strength of Nxera’s NxWave discovery platform in addressing complex neurological disorders.
For further insights into JP:4565 stock, check out TipRanks’ Stock Analysis page.